ReviewCancer journal (Sudbury, Mass.)
Radiotherapy for Non-Hodgkin Lymphomas.
Review in Cancer journal (Sudbury, Mass.). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 27 citations in OpenAlex.
- MR-Linac Successfully Guided the Treatment of a Free-Moving Mesenteric Mass.Precision radiation oncology · 2026Article
- Quadshot Radiotherapy as Bridging Therapy for Adult Lymphoma Patients: A Single-Institutional Experience.Advances in radiation oncology · 2026Article
- Survival Prediction in Middle-Aged and Elderly Patients With Burkitt Lymphoma: A Comprehensive Nomogram Approach Based on SEER Data.Cancer medicine · 2025Article
- Epidemiological analysis of radiation therapy utilization and its implications for cancer care in India-insights from National Cancer Registry Programme.BMC cancer · 2025Article
- Cardiovascular disease in adolescent and young adult survivors of non-Hodgkin lymphoma in Korea.Journal of cancer survivorship : research and practice · 2025Article
- Primary Palatine Tonsil Non-Hodgkin Lymphoma in Western Romania: A Comparison of Lower-Stage and Advanced-Stage Disease.Hematology reports · 2025Article
- Odd Ball Paradigms of Rhino Facial Swellings: A Diagnostic Dilemma of Primary Subcutaneous Non-Hodgkin Lymphomas.Journal of maxillofacial and oral surgery · 2025Article
- Cancer radioresistance is characterized by a differential lipid droplet content along the cell cycle.Cell division · 2024Article
- The Gut Connection: Exploring the Possibility of Implementing Gut Microbial Metabolites in Lymphoma Treatment.Cancers · 2024Review
- Article
- Prevalence of non-Hodgkin lymphoma patients at high-risk of failure after CAR T-cell therapy eligible for bridging radiation therapy.Frontiers in oncology · 2024Article
- Beyond surgery: the proper role and delivery of radiation therapy in the local-regional management of BIA-ALCL.Case reports in plastic surgery & hand surgery · 2024Article
- Design Characteristics and Recruitment Rates for Randomized Trials of Peri-Prosthetic Joint Infection Management: A Systematic Review.Antibiotics (Basel, Switzerland) · 2023Review
- Efficacy and toxicity of infradiaphragmal radiotherapy fields in lymphoma patients: a single-centre experience.La Radiologia medica · 2023Article
- Salvage radiotherapy for primary refractory and relapsed diffuse large B-Cell lymphoma.The British journal of radiology · 2021Review
- Long-term remission and survival in dogs with high-grade, B cell lymphoma treated with chemotherapy with or without sequential low-dose rate half-body irradiation.Journal of veterinary internal medicineArticle
- Safety of Concurrent Radiation Therapy With Brentuximab Vedotin in the Treatment of Lymphoma.Advances in radiation oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Radiotherapy (RT) plays a diverse and essential role in the contemporary management of non-Hodgkin lymphoma (NHL) and remains the single most powerful monotherapeutic intervention for both aggressive and indolent subtypes. Over the past decade, there have been significant advancements in radiation oncology practice, which have made modern treatments safer and more conformal. Despite this sophistication and evidence supporting a continued role for RT, numerous data suggest that utilization is on the decline. In this review, we discuss the rationale for RT in 4 commonly encountered scenarios: combined modality therapy for limited-stage aggressive NHL, consolidation therapy for advanced-stage aggressive NHL, and the changing roles of salvage RT for relapsed/refractory NHL in an era of new frontiers such as cellular therapies. We also evaluate current strategies to treat indolent histologies. We conclude with perspectives on how RT for the hematological malignancies may continue to evolve.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.